(1) Olivares-Hern‡ndez A (2) Figuero-PŽrez L (3) Ter‡n-Brage E (4) L—pez-GutiŽrrez ç (5) Velasco çT (6) Sarmiento RG (7) Cruz-Hern‡ndez JJ (8) Miramontes-Gonz‡lez JP

Journal of clinical medicine

Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.

Author Info: (1) Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain. Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. (2) De

Author Info: (1) Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain. Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. (2) Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain. Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. (3) Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain. Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. (4) Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain. Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. (5) Department of Haematology, University Hospital of Valladolid, 47003 Valladolid, Spain. (6) Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. Department of Medicine, University of Salamanca, 37007 Salamanca, Spain. (7) Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain. Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain. Department of Medicine, University of Salamanca, 37007 Salamanca, Spain. (8) Department of Internal Medicine, University Hospital Rio Hortega, 47012 Valladolid, Spain. Department of Medicine, University of Valladolid, 45005 Valladolid, Spain.

Citation: J Clin Med 2021 Apr 28 10: Epub04/28/2021

Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/33925214

Tags: